ILCA warmly thanks all Partners and Sponsors for their unrestricted support to the 2016 Annual Conference and their commitment to help advance liver cancer science.

Diamond Partner


Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer’s oncology franchise now includes more than three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

Gold Partner


Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

For more information about Bristol-Myers Squibb, visit or follow us on Twitter.


Sirtex Medical is actively engaged in the field of liver-directed therapies for cancer patients.
Our innovative technology, SIR-Spheres® microspheres (Yttrium-90 resin beads), was approved in 2002 for use in the treatment of a variety of unresectable liver tumours a well as in hepatocellular carcinoma within the European Union under a CE Mark. SIR-Spheres® microspheres are presently used at more than 250 institutions in Europe.

®SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd



BTG is an international specialist healthcare company. Our growing portfolio of Interventional Medicine therapies is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins. No company does more to help doctors in their quest to see more, reach further and treat



Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company’s lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a phase III clinical trial (OPTIMA Study) for primary liver cancer.


For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit



Media Partners